Literature DB >> 8718851

Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases.

L Hong1, A Treharne, J A Hartsuck, S Foundling, J Tang.   

Abstract

Crystal structures of the protease of human immunodeficiency virus type 1 (HIV-1) and two mutant proteases, V82D and V82N, have been determined. In all three cases the enzyme forms a complex with the peptidic inhibitor U-89360E. All structures have been determined to 2.3 A resolution and have satisfactory agreement factors: 0.173 for wild type, 0.175 for V82D, and 0.182 for V82N. Comparison of the three crystal structures provides explanations which are consistent with the known kinetic properties of these mutant enzymes with the U-89360E inhibitor [Lin, Y., Lin, X., Hong, L., Foundling, S., Heinrikson, R. L., Thaisrivongs, S., Leelamanit, W., Raterman, D., Shah, M., Dunn, B.M., & Tang, J. (1995) Biochemistry 34, 1143-1152]. Unfavorable van der Waals interactions between the inhibitor and the mutated side chains at position 82 are consistent with diminished affinity for the inhibitor by the mutant enzymes. If a mutation is potentially resistant to an inhibitor, the mutant enzyme should not only have an increased Ki for the inhibitor but should also preserve considerable catalytic capability. The V82D mutant possesses these qualities. In the V82D crystal structure, a water molecule, which connects the protease flap to the inhibitor, is missing or of low occupancy. Absence of this bridge may be important in determining catalytic capability. Moreover, mutation at position 82 induces change in two polypeptide backbone regions, 35-41 and 67-68, which may be related to protease flap mobility.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8718851     DOI: 10.1021/bi960481s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Authors:  Nancy M King; Laurence Melnick; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Shiow-Shong Yang; Yun Gao; Xiaoyi Nie; Charles Zepp; Donald L Heefner; Celia A Schiffer
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

2.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Inhibition and substrate recognition--a computational approach applied to HIV protease.

Authors:  H M Vinkers; M R de Jonge; E D Daeyaert; J Heeres; L M H Koymans; J H van Lenthe; P J Lewi; H Timmerman; P A J Janssen
Journal:  J Comput Aided Mol Des       Date:  2003-09       Impact factor: 3.686

4.  Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

Authors:  Hiroyasu Ohtaka; Adrian Velázquez-Campoy; Dong Xie; Ernesto Freire
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

5.  Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations.

Authors:  Kitiyaporn Wittayanarakul; Ornjira Aruksakunwong; Suwipa Saen-oon; Wasun Chantratita; Vudhichai Parasuk; Pornthep Sompornpisut; Supot Hannongbua
Journal:  Biophys J       Date:  2004-11-12       Impact factor: 4.033

6.  Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants.

Authors:  F Sussman; M C Villaverde; A Davis
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

7.  Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.

Authors:  L Hong; X C Zhang; J A Hartsuck; J Tang
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

8.  Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant.

Authors:  L Hong; J A Hartsuck; S Foundling; J Ermolieff; J Tang
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

9.  Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Sarang Kulkarni; David D Anderson; Lin Hong; Abigail Baldridge; Yuan-Fang Wang; Alexander A Chumanevich; Andrey Y Kovalevsky; Yasushi Tojo; Masayuki Amano; Yasuhiro Koh; Jordan Tang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations.

Authors:  Ekachai Jenwitheesuk; Ram Samudrala
Journal:  BMC Struct Biol       Date:  2003-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.